The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis
Konstan, M. W., Byard, P. J., Hoppel, C. L., & Davis, P. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321303 · Cited by 726
Self-citationPulmonary function between 6 and 18 years of age
Wang, X., Dockery, D. W., Wypij, D., Fay, M. E., & Ferris, B. G. (1993) · Pediatric Pulmonology · doi:10.1002/ppul.1950150204 · Cited by 648
Konstan, M. W., Hilliard, K. A., Norvell, T. M., & Berger, M. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.2.8049828 · Cited by 520
Self-citationGenetic Modifiers of Lung Disease in Cystic Fibrosis
Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F., Zariwala, M., Fargo, D., Xu, A., Dunn, J. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051469 · Cited by 504
Self-citationMILLA, C. E., WARWICK, W. J., & MORAN, A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9904075 · Cited by 367
de Jong, P. A., Nakano, Y., Lequin, M. H., Mayo, J. R., Woods, R., Paré, P. D., & Tiddens, H. A. W. M. (2004) · European Respiratory Journal · doi:10.1183/09031936.03.00006603 · Cited by 318
Zemel, B. S., Jawad, A. F., FitzSimmons, S., & Stallings, V. A. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.107891 · Cited by 311
Kerem, E., Corey, M., Gold, R., & Levison, H. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82653-8 · Cited by 306
Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection
Demko, C. A., Byard, P. J., & Davis, P. B. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00230-n · Cited by 289
Cited by
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Sanders, D. B., Bittner, R. C. L., Rosenfeld, M., Hoffman, L. R., Redding, G. J., & Goss, C. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1421oc · Cited by 519
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-10 · Cited by 411
MacKenzie, T., Gifford, A. H., Sabadosa, K. A., Quinton, H. B., Knapp, E. A., Goss, C. H., & Marshall, B. C. (2014) · Annals of Internal Medicine · doi:10.7326/m13-0636 · Cited by 355
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
de Boer, K., Vandemheen, K. L., Tullis, E., Doucette, S., Fergusson, D., Freitag, A., Paterson, N., Jackson, M., Lougheed, M. D., Kumar, V., et al. (2011) · Thorax · doi:10.1136/thx.2011.161117 · Cited by 271
“Pulmonary exacerbations of CF, chronic obstructive pulmonary disease (COPD) and asthma are clearly serious events and have recently been coined ‘lung attacks’.”
BackgroundKonstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D., Huang, X., Lubarsky, B., Rubin, J., Millar, S. J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 259
Self-citationVolkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.015 · Cited by 258
Self-citationEffect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Waters, V., Stanojevic, S., Atenafu, E. G., Lu, A., Yau, Y., Tullis, E., & Ratjen, F. (2012) · European Respiratory Journal · doi:10.1183/09031936.00159111 · Cited by 256
“Within the spectrum of illness that can be considered a pulmonary exacerbation, severe pulmonary exacerbations requiring intravenous antibiotics has clearly been shown to be associated with lung function decline[4,6], such that a quarter of adult and pediatric CF patients do not recover their baseline FEV1[7,8].”
BackgroundEpidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis
Parkins, M. D., Somayaji, R., & Waters, V. J. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-18 · Cited by 253
Sawicki, G. S., McKone, E. F., Pasta, D. J., Millar, S. J., Wagener, J. S., Johnson, C. A., & Konstan, M. W. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0578oc · Cited by 236
Self-citationCystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Carmody, L. A., Zhao, J., Kalikin, L. M., LeBar, W., Simon, R. H., Venkataraman, A., Schmidt, T. M., Abdo, Z., Schloss, P. D., & LiPuma, J. J. (2015) · Microbiome · doi:10.1186/s40168-015-0074-9 · Cited by 135
“Although clinical management based on antibiotic treatment and intensified airway clearance is usually at least partially effective [10-12], patients fail to return to 100% of baseline lung function in greater than 40% of exacerbations treated with intravenous antibiotics [13].”
Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
Stressmann, F. A., Rogers, G. B., Marsh, P., Lilley, A. K., Daniels, T. W. V., Carroll, M. P., Hoffman, L. R., Jones, G., Allen, C. E., Patel, N., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.05.002 · Cited by 130
“Exacerbations are risk factors for a more rapid lung function decline [6], and recent evidence indicates that loss of lung function that occurs during exacerbations can be permanent [7].”
BackgroundLung function decline from adolescence to young adulthood in cystic fibrosis
VandenBranden, S. L., McMullen, A., Schechter, M. S., Pasta, D. J., Michaelis, R. L., Konstan, M. W., Wagener, J. S., Morgan, W. J., McColley, S. A., & for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (2012) · Pediatric Pulmonology · doi:10.1002/ppul.21526 · Cited by 128
Self-citationRisk factors for rate of decline in FEV1 in adults with cystic fibrosis
Konstan, M. W., Wagener, J. S., VanDevanter, D. R., Pasta, D. J., Yegin, A., Rasouliyan, L., & Morgan, W. J. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.03.009 · Cited by 115
Self-citationYear-to-year changes in lung function in individuals with cystic fibrosis
Liou, T. G., Elkin, E. P., Pasta, D. J., Jacobs, J. R., Konstan, M. W., Morgan, W. J., & Wagener, J. S. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.04.002 · Cited by 110
Self-citationSanders, D. B., & Fink, A. K. (2016) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2016.04.001 · Cited by 109
Sawicki, G. S., Rasouliyan, L., McMullen, A. H., Wagener, J. S., McColley, S. A., Pasta, D. J., & Quittner, A. L. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21325 · Cited by 106
“Only small improvements in lung function were noted for children, whereas the decline in lung function for adolescents and adults was similar to published data as well as data from the CF Foundation Patient Registry.(16) Changes in treatment complexity mirrored these findings,”
ResultSelf-citationLai, H. J., Shoff, S. M., Farrell, P. M., & with the Wisconsin Cystic Fibrosis Neonatal Screening Group (2009) · Pediatrics · doi:10.1542/peds.2007-3089 · Cited by 106
Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis
Amadori, A., Antonelli, A., Balteri, I., Schreiber, A., Bugiani, M., & De Rose, V. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.09.024 · Cited by 64
Kirwan, L., Fletcher, G., Harrington, M., Jeleniewska, P., Zhou, S., Casserly, B., Gallagher, C. G., Greally, P., Gunaratnam, C., Herzig, M., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-149oc · Cited by 58
Characterizing aggressiveness and predicting future progression of CF lung disease
Konstan, M. W., Wagener, J. S., & VanDevanter, D. R. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60006-0 · Cited by 55
Self-citationFlume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30510-5 · Cited by 52
Self-citationThe impact of CFTR modulator therapies on CF airway microbiology
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 52
Fidika, A., Herle, M., & Goldbeck, L. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-205 · Cited by 46
Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression
Szczesniak, R. D., Su, W., Brokamp, C., Keogh, R. H., Pestian, J. P., Seid, M., Diggle, P. J., & Clancy, J. P. (2020) · Statistics in Medicine · doi:10.1002/sim.8443 · Cited by 30
“Although previous studies identified early adolescence/adulthood as high risk, 3,8,9 we found that risk of rapid decline varied considerably between patients and within a given patient during this period.”
BackgroundHoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
Szczesniak, R. D., Brokamp, C., Su, W., Mcphail, G. L., Pestian, J., & Clancy, J. P. (2019) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2018.2878534 · Cited by 15
“Numerous epidemiologic studies by these authors [4] and others [5]–[7] have employed various statistical approaches to estimate trajectories of lung function decline.”
Metadata
- Authors
- Konstan, M. W., Morgan, W. J., Butler, S. M., Pasta, D. J., Craib, M. L., Silva, S. J., Stokes, D. C., Wohl, M. E. B., Wagener, J. S., Regelmann, W. E., & Johnson, C. A.
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 151
- Issue
- 2
- Pages
- 134-139.e1
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W2109939030
- Cited by
- 438
- References
- 23
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.